Verastem, Inc. Payments to Acquire Debt Securities, Available-for-sale
Verastem, Inc. (VSTM) reported Payments to Acquire Debt Securities, Available-for-sale of $16.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Verastem, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $0.00.
- Verastem, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $16.02M.
- Verastem, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2023-12-31 was $12.56M, a 407.64% increase year-over-year.
- Verastem, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2023-09-30 was $70.08M, a 576.90% increase year-over-year.
- Verastem, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $96.45M, a 441.38% increase from fiscal 2022.
- Verastem, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $17.82M, a 79.39% decline from fiscal 2021.
- Verastem, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $86.44M, a 8.90% increase from fiscal 2020.
- Verastem, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $79.38M, a 15.66% decline from fiscal 2019.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.02M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $16.02M 10-Q · filed 2026-05-07 | |||
| 2023-12-31 | $12.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $82.64M derived: sum of 2 quarters · filed 2026-03-04 | $82.64M derived: sum of 3 quarters · filed 2026-03-04 | $96.45M 10-K · filed 2026-03-04 |
| 2023-09-30 | $70.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $70.08M derived: sum of 2 quarters · filed 2024-11-06 | $83.88M 10-Q · filed 2024-11-06 | $86.36M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.80M 10-Q · filed 2024-08-08 | $16.28M derived: sum of 3 quarters · filed 2025-03-20 | $26.63M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-03-31 | $13.80M 10-Q · filed 2024-05-09 | $16.28M derived: sum of 2 quarters · filed 2025-03-20 | $26.63M derived: sum of 3 quarters · filed 2025-03-20 | $26.63M derived: sum of 4 quarters · filed 2025-03-20 |
| 2022-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $12.83M derived: sum of 2 quarters · filed 2025-03-20 | $12.83M derived: sum of 3 quarters · filed 2025-03-20 | $17.82M 10-K · filed 2025-03-20 |
| 2022-09-30 | $10.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $10.35M derived: sum of 2 quarters · filed 2023-11-08 | $15.34M 10-Q · filed 2023-11-08 | $48.52M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.99M 10-Q · filed 2023-08-08 | $38.17M derived: sum of 3 quarters · filed 2024-03-14 | $38.17M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $4.99M 10-Q · filed 2023-05-09 | $38.17M derived: sum of 2 quarters · filed 2024-03-14 | $38.17M derived: sum of 3 quarters · filed 2024-03-14 | $73.88M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $33.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $33.18M derived: sum of 2 quarters · filed 2024-03-14 | $68.89M derived: sum of 3 quarters · filed 2024-03-14 | $86.44M 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $35.71M derived: sum of 2 quarters · filed 2022-11-03 | $53.26M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $35.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $53.26M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $17.55M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $79.38M 10-K · filed 2023-03-14 | |||
| 2019-12-31 | $20.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $56.49M derived: sum of 2 quarters · filed 2022-03-28 | $56.49M derived: sum of 3 quarters · filed 2022-03-28 | $94.12M 10-K · filed 2022-03-28 |
| 2019-09-30 | $35.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $35.55M derived: sum of 2 quarters · filed 2020-11-09 | $73.19M 10-Q · filed 2020-11-09 | $183.73M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $37.64M 10-Q · filed 2020-08-10 | $148.18M derived: sum of 3 quarters · filed 2021-03-18 | |
| 2019-03-31 | $37.64M 10-Q · filed 2020-05-07 | $148.18M derived: sum of 2 quarters · filed 2021-03-18 | ||
| 2018-12-31 | $110.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $125.45M 10-K · filed 2021-03-18 | ||
| 2018-09-30 | $14.91M 10-Q · filed 2019-10-30 | |||
| 2017-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $1.50M derived: sum of 2 quarters · filed 2020-03-11 | $1.50M derived: sum of 3 quarters · filed 2020-03-11 | $7.96M 10-K · filed 2020-03-11 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $6.46M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $6.46M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $6.46M 10-Q · filed 2018-05-03 | |||
| 2016-12-31 | $82.10M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |